These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. Groman JD; Meyer ME; Wilmott RW; Zeitlin PL; Cutting GR N Engl J Med; 2002 Aug; 347(6):401-7. PubMed ID: 12167682 [TBL] [Abstract][Full Text] [Related]
6. Distinctive metabolic profiles between Cystic Fibrosis mutational subclasses and lung function. Masood A; Jacob M; Gu X; Abdel Jabar M; Benabdelkamel H; Nizami I; Li L; Dasouki M; Abdel Rahman AM Metabolomics; 2021 Jan; 17(1):4. PubMed ID: 33394183 [TBL] [Abstract][Full Text] [Related]
7. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Mickle JE; Cutting GR Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548 [TBL] [Abstract][Full Text] [Related]
8. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis. Yeh JT; Yu YC; Hwang TC J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177 [TBL] [Abstract][Full Text] [Related]
9. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine. Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274 [TBL] [Abstract][Full Text] [Related]
10. Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis. McCague AF; Raraigh KS; Pellicore MJ; Davis-Marcisak EF; Evans TA; Han ST; Lu Z; Joynt AT; Sharma N; Castellani C; Collaco JM; Corey M; Lewis MH; Penland CM; Rommens JM; Stephenson AL; Sosnay PR; Cutting GR Am J Respir Crit Care Med; 2019 May; 199(9):1116-1126. PubMed ID: 30888834 [No Abstract] [Full Text] [Related]
12. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis. Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331 [TBL] [Abstract][Full Text] [Related]
14. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Mickle JE; Macek M; Fulmer-Smentek SB; Egan MM; Schwiebert E; Guggino W; Moss R; Cutting GR Hum Mol Genet; 1998 Apr; 7(4):729-35. PubMed ID: 9499426 [TBL] [Abstract][Full Text] [Related]
15. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. Cohn JA; Friedman KJ; Noone PG; Knowles MR; Silverman LM; Jowell PS N Engl J Med; 1998 Sep; 339(10):653-8. PubMed ID: 9725922 [TBL] [Abstract][Full Text] [Related]
16. [Expression of the cystic fibrosis gene in the lungs]. Heijerman HG; de Jonge HR Ned Tijdschr Geneeskd; 2004 Apr; 148(17):816-9. PubMed ID: 15141646 [TBL] [Abstract][Full Text] [Related]
17. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis. Cuyx S; De Boeck K Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC; Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620 [TBL] [Abstract][Full Text] [Related]